基于CiteSpace的SGLT2抑制剂治疗心力衰竭的可视化分析

Visualization analysis of SGLT2 inhibitors in the treatment of heart failure based on CiteSpace

目的采用CiteSpace软件可视化分析钠葡萄糖协同转运蛋白2(SGLT2)抑制剂治疗心力衰竭(HF)相关研究的文献篇数、发文作者、研究机构以及关键词,探索SGLT2抑制剂治疗HF的发展状况、研究热点及研究前沿。方法以Web of Science核心合集数据库为检索源,基于Java平台的文献计量学CiteSpace V软件对纳入的文献进行处理分析,并得出相关知识图谱。结果Web of Science数据库自1997年发布以来收录的关于SGLT2抑制剂治疗HF研究的英文文章最早发表于2012年,该领域发文数量从2012—2021年呈上升趋势,说明该领域仍处于发展阶段。本研究共纳入文献1051篇,美国共发文471篇,为该领域发文量最多的国家。发文数量最多的研究机构是加拿大的多伦多大学,各研究机构之间合作较少,且较为分散。可视化分析后得出该领域研究热点主要为糖尿病、心血管疾病及慢性肾病在SGLT2抑制剂治疗中的获益及其作用机制。结论该领域目前的研究热点之一是HF在运用SGLT2抑制剂治疗中的获益情况,逐步拓展到其他心血管疾病如房颤、心肌梗死等及慢性肾病患者在运用SGLT2抑制剂治疗中是否获益,这类药物可以改善糖尿病患者的预后、降低HF患者的死亡率、减少糖尿病患者肾功能衰竭的发生,并可以通过优化血容量起到一定的降压等作用,且目前只有SGLT2抑制剂具备以上多重功效。故推测,SGLT2抑制剂具有广阔的临床应用前景。

Objective To visually analyze the number of papers,authors,research institutions and keywords related to sodium-glucose cotransporter 2(SGLT2)inhibitors in the treatment of heart failure(HF)by using CiteSpace,and to explore the development status,research hotspots and research frontiers of SGLT2 inhibitors in the treatment of HF.Methods The core collection database of Web of Science was used as the retrieval source,the bibliometric software CiteSpace V based on Java platform was used to process and analyze the included papers,and the relevant knowledge graph was obtained.Results Since the publication of Web of Science database in 1997,the English papers on SGLT2 inhibitors in the treatment of HF were first published in 2012,and the number of papers in this field showed an increasing trend from 2012 to 2021,indicating that this field was still in the development stage.A total of 1051 papers were included in this study,including 471 papers from the United States,the country with the largest number of papers in this field.The research institution with the largest number of papers was the University of Toronto in Canada,and the cooperation among the research institutions was less and scattered.The research hotspots in this field were mainly the benefit of SGLT2 inhibitors in the treatment of diabetes mellitus,cardiovascular diseases and chronic kidney disease and their mechanism of action.Conclusion One of the current research hotspots in this field is the benefit of SGLT2 inhibitors in the treatment of HF,which has been gradually expanded to the benefit of SGLT2 inhibitors in the treatment of other cardiovascular diseases such as atrial fibrillation and myocardial infarction,and chronic kidney disease.These drugs can improve the prognosis of diabetic patients,reduce the mortality of HF patients,reduce the occurrence of renal failure in diabetic patients,and play a certain role in lowering blood pressure by optimizing blood volume.At present,only SGLT2 inhibitors have the above multiple effects.Therefore,it is speculated that SGLT2 inhibitors have broad clinical application prospects.